74 episodes

Cell & Gene, the most valuable online resource for delivering in-depth content from authoritative authors and sources to professionals in the CGT sector, introduces Cell & Gene: The Podcast. In each episode, Cell & Gene Chief Editor, Erin Harris, will talk to industry and academic leaders about their current initiatives and how they are moving the sector forward.

Cell & Gene: The Podcast Erin Harris

    • Science
    • 4.9 • 36 Ratings

Cell & Gene, the most valuable online resource for delivering in-depth content from authoritative authors and sources to professionals in the CGT sector, introduces Cell & Gene: The Podcast. In each episode, Cell & Gene Chief Editor, Erin Harris, will talk to industry and academic leaders about their current initiatives and how they are moving the sector forward.

    Reducing the Disease Burden of AML with Vor Bio's Dr. Robert Ang

    Reducing the Disease Burden of AML with Vor Bio's Dr. Robert Ang

    In 2021 on Episode 13, Vor Bio’s President and CEO, Dr. Robert Ang shared data about the company’s lead engineered hematopoietic cell (eHSC) product candidate. Dr. Ang is back to talk to Cell & Gene: The Podcast Host, Erin Harris, about how Vor has treated 8 patients demonstrating clinical proof of concept and is also in the clinic with a CAR-T that could be used in combination with shielded stem cell transplants. They also talk through Vor’s decision to build an internal cell therapy manufacturing facility co-located with their Cambridge, MA-based headquarters.

    • 23 min
    Reducing Toxicities in Allogeneic Cell Therapies with Orca Bio's Dr. Scott McClellan

    Reducing Toxicities in Allogeneic Cell Therapies with Orca Bio's Dr. Scott McClellan

    Orca Bio's CMO, Dr. Scott McClellan, joins Erin Harris on this episode of Cell & Gene: The Podcast to discuss how and why toxicities continue to stymie allogeneic cell therapies. They cover Orca Bio's plan to potentially lowering the risk of GvHD as well as Orca-T, the investigational high-precision allogeneic cell therapy being evaluated in clinical trials for the treatment of multiple hematologic malignancies.

    • 19 min
    Inside Cellular Rejuvenation Therapies for Age-Related Diseases with Life Biosciences' Sharon Rosenzweig-Lipson, Ph.D.

    Inside Cellular Rejuvenation Therapies for Age-Related Diseases with Life Biosciences' Sharon Rosenzweig-Lipson, Ph.D.

    On this episode of Cell & Gene: The Podcast, Host Erin Harris talks to Life Biosciences' CSO, Sharon Rosenzweig-Lipson, Ph.D., about the Boston-based biotech's cellular rejuvenation therapies for the treatment of age-related diseases. They cover Life Biosciences' lead program, a gene therapy called OSK that is being advanced in two optic neuropathies – a rare eye disease of aging called non-arteritic anterior ischemic optic neuropathy (NAION) and glaucoma. They also cover they why behind gene therapy as a modality, as well as Life Biosciences' partnership with Forge Biologics to manufacture AAV for the cellular rejuvenation technology.

    • 17 min
    The Future of Rare Diseases with The Jackson Laboratory’s Rare Disease Translational Center's Cat Lutz

    The Future of Rare Diseases with The Jackson Laboratory’s Rare Disease Translational Center's Cat Lutz

    Rare Disease Day is February 29, 2024, and in honor of this important day, Cell & Gene: The Podcast Host Erin Harris sits down with Jackson Laboratory’s (JAX) Rare Disease Translational Center (RDTC)'s VP, Cat Lutz. They discuss RDTC's mission, the specific qualifications that make up a rare disease, how the study of rare diseases can potentially advance progress in common diseases, and much more. 

    • 27 min
    Inside Yescarta's Reduced Median Turnaround Time with Kite, a Gilead company's Christopher McDonald

    Inside Yescarta's Reduced Median Turnaround Time with Kite, a Gilead company's Christopher McDonald

    On this episode of Cell & Gene: The Podcast, Christopher McDonald, Global Head of Technical Operations at Kite, a Gilead company, talks to Host Erin Harris about Kite's recent FDA approval of manufacturing process change resulting in reduced median turnaround time for Yescarta. They talk through the most significant steps Kite took to reach this approval, lessons learned from having worked with the FDA, scaling up technologies for cell therapy manufacturing, and more. 

    • 20 min
    Pricing, Value, And Access of CGTs With The Dedham Group's Jennifer Klarer, M.Sc.Eng.

    Pricing, Value, And Access of CGTs With The Dedham Group's Jennifer Klarer, M.Sc.Eng.

    The Dedham Group's Jennifer Klarer, M.Sc.Eng., Partner and Head of Cell & Gene Therapy, joins Erin Harris on this episode of Cell & Gene: The Podcast for a deep dive into pricing and value for CGTs. Klarer shares a detailed breakdown of the most misunderstood aspects of cell and gene therapy pricing, value, and affordability. She details how manufacturers can get ahead of addressing time to treatment issues typically experienced at launch. They cover obtaining adequate investment dollars, and much more. 

    • 37 min

Customer Reviews

4.9 out of 5
36 Ratings

36 Ratings

buck025 ,

Top Notch Podcast

I’ve learned a great deal listening to this podcast. Erin Harris does a fantastic job of keeping the topics current and the guests she has on are all leaders in the industry.

Derek VS ,

Must listen for anyone in this market

If you’re interested in what the leaders of the cell therapy and gene therapy market think, this is well worth a subscribe.

MoodyPooty ,

Required Listening

The cell and gene space is growing and developing quickly. The Cell and Gene Podcast is the best way to keep up with this exciting and quickly developing segment of the pharma industry.

Top Podcasts In Science

Hidden Brain
Hidden Brain, Shankar Vedantam
Something You Should Know
Mike Carruthers | OmniCast Media | Cumulus Podcast Network
Radiolab
WNYC Studios
Reinvent Yourself with Dr. Tara
Dr. Tara Swart Bieber
Ologies with Alie Ward
Alie Ward
StarTalk Radio
Neil deGrasse Tyson

You Might Also Like

Business Of Biotech
Matt Pillar
The Readout Loud
STAT
Raising Health
Andreessen Horowitz
ASGCT Podcast Network
American Society of Gene & Cell Therapy
Nature Podcast
Springer Nature Limited
Odd Lots
Bloomberg